Tag - KMDA

Executive Moves

Kamada transitions CFO; launches search for successor

Kamada (NASDAQ: KMDA; TASE: KMDA.TA) has announced that CFO Chaime Orlev will step down effective December 31, 2026, to pursue other opportunities and will provide transitional support to the incoming CFO. The company...

August 12, 2026

Developments

Kamada IgG therapy cleared for compassionate COVID-19 use in Israel

Kamada (NASDAQ, TASE:KMDA) completed manufacturing of the first batch of its plasma-derived immunoglobulin (IgG) product for the treatment of COVID-19 and the initial vials are available for compassionate use in Israel...

June 17, 2020

Developments

Kamada enrolls first patient in Phase 3 alpha-1 antitrypsin deficiency trial

Kamada (NASDAQ, TASE:KMDA) randomized the first patient in a pivotal clinical trial evaluating its inhaled alpha-1 antitrypsin (AAT) therapy for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an...

December 17, 2019

Developments

Kamada in pact with Alvotech to commercialization 6 biosimilars in Israel

Kamada (NASDAQ, TASE:KMDA) agreed to commercialize Alvotech’s portfolio of six biosimilar product candidates in Israel, pending approval of the Israeli Ministry of Health (IMOH). Alvotech’s pipeline includes biosimilar...

December 2, 2019

Tag - KMDA

Kamada transitions CFO; launches search for successor

Kamada IgG therapy cleared for compassionate COVID-19 use in Israel

Kamada enrolls first patient in Phase 3 alpha-1 antitrypsin deficiency trial

Kamada in pact with Alvotech to commercialization 6 biosimilars in Israel

Subscribe